The U.S. authorized a brand new COVID-19 vaccine made by Moderna late Friday however with limits on who can use it — not a alternative for the corporate’s present shot, however a second possibility.
The brand new vaccine, mNexspike, is a step towards next-generation coronavirus vaccines. It is made in a approach that permits for a decrease dose — a fifth of the dose of its present COVID-19 vaccine, Spikevax — by refining its immune goal.
The approval “provides an essential new software to assist shield individuals at excessive danger of extreme illness from COVID-19,” Stephane Bancel, Moderna’s CEO, mentioned in an announcement Saturday.
The Meals and Drug Administration authorized the brand new vaccine to be used in all adults 65 and older, and for individuals age 12 to 64 who’ve a least one well being situation that places them at elevated danger from the coronavirus.
That’s the identical restrict that the FDA set in licensing one other COVID-19 vaccine possibility from competitor Novavax.
These restrictions are a departure from how the U.S. has dealt with COVID-19 vaccines till now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and different Trump officers.
Moderna’s present vaccine doesn’t face these limits and has lengthy been used for anybody ages 6 months and older. The corporate mentioned it anticipated to supply each choices this fall.
The FDA’s approval was primarily based on a research of 11,400 individuals age 12 and older that in contrast the brand new low-dose vaccine with Moderna’s present vaccine. It discovered the brand new vaccine was protected and was a minimum of as efficient — and extra by some measures — than the unique shot, the corporate mentioned.
The information got here simply days after the Trump administration canceled funding for Moderna to develop a vaccine towards potential pandemic flu viruses, together with the H5N1 fowl flu, regardless of promising early research outcomes.
___
The Related Press Well being and Science Division receives assist from the Howard Hughes Medical Institute’s Science and Academic Media Group and the Robert Wooden Johnson Basis. The AP is solely accountable for all content material.
